Sources last read
Zepbound dosage schedule
Zepbound starts at 2.5 mg once a week. Its maximum dose is 15 mg. Only 5, 10, 15 mg are doses the label says you can stay on.
Source for this answer
Source: Read from the Zepbound label, revision 08/2026
Source: Read from the Zepbound label, revision 08/2026
Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewerReviewed 2026-08-12every number here is sourced
Key dose facts
Key facts
- 2.5 mg once a week
- 5, 10 and 15 mg
- 15 mg once a week
- Shown step by step below
The Zepbound dosages, step by step
The label prints the 2.5 mg start and the move to 5 mg after 4 weeks. After that, it allows 2.5 mg increases after at least 4 weeks on the current dose, but it does not print one fixed calendar.
| When | Weekly dose | Can you stay here? | What the label notes |
|---|---|---|---|
| Weeks 1 through 4 | 2.5 mg | No — a step only | Starting dosage — not approved as a maintenance dosage |
| After 4 weeks | 5 mg | Yes | Lowest maintenance option |
Which dose do you end up on?
The label names 5 mg, 10 mg and 15 mg as the maintenance dosages for weight reduction, and 10 mg or 15 mg for sleep apnea. 7.5 mg and 12.5 mg appear only as steps on the way up.
| Who the label covers | Dose to settle on | Approved |
|---|---|---|
| Adults with obesity, or adults with overweight and at least one weight-related comorbid condition, alongside a reduced-calorie diet and increased physical activity | 5 mg, 10 mg or 15 mg once weekly | 2023-11-08NDA 217806 |
| Adults with obesity who have moderate to severe obstructive sleep apnea. This was the first drug treatment the FDA approved for obstructive sleep apnea | 10 mg or 15 mg once weekly | 2024-12-20NDA 217806/S-013 |
15 mg once weekly is the maximum for every approved use of Zepbound. The label sets no higher dose.
12Label details
Who does the label cover, and who does it not?
Both approved uses are written for adults. The label sets no dose for anyone under 18.
The Zepbound label covers neither type 2 diabetes nor anyone under 18. It also says not to take it alongside another tirzepatide product, or any GLP-1 receptor agonist.
What if a week gets missed?
The label says a missed dose can be given within 4 days, which is 96 hours. Past 4 days it says to skip that week and go back to the usual day.
The label allows the weekly day to move as long as two doses stay at least 3 days, or 72 hours, apart.
What does it come in?
The device matters for dosing, because some of these hold one dose and some hold four.
| Device | Strengths | Doses inside |
|---|---|---|
| Single-dose pen | 2.5, 5, 7.5, 10, 12.5 and 15 mg per 0.5 mL | 1 dose |
| Single-dose vial | 2.5, 5, 7.5, 10, 12.5 and 15 mg per 0.5 mL | 1 dose |
| Multi-dose vial | 10 to 60 mg per 2.4 mL, delivering 2.5 to 15 mg per 0.6 mL dose | 4 doses |
| Single-patient-use KwikPen | 10 to 60 mg per 2.4 mL, delivering 2.5 to 15 mg per dose | 4 doses |
Zepbound and Mounjaro are the same drug. So why are the doses different?
Mounjaro is the same drug substance from the same manufacturer, approved for type 2 diabetes rather than weight, and it covers children from age 10 where Zepbound covers nobody under 18.
Both products contain tirzepatide, and both come from Eli Lilly and Company. They were approved under separate applications, NDA 217806 and NDA 215866. Each label sets out its approved uses, dose schedule and instructions for a missed dose.
The highest labeled doses are 15 mg for Zepbound and 15 mg for Mounjaro. Their shared ingredient does not make their dose plans interchangeable.
Both labels print 2.5 and 5 mg. Those are the same amounts of tirzepatide on either label. What changes is where each one sits. 2.5 mg is a step you pass through on Zepbound, and a dose the Mounjaro label says you can stay on.
How long does it take to reach the 15 mg dose?
The label does not promise one date. It sets the timing for each step in the schedule below.
Zepbound starts at 2.5 mg and has a 15 mg ceiling. Read the published timing beside each row rather than adding the waits into one calendar estimate.
Nothing in the label says a person has to keep climbing. The maintenance choices are listed separately below.
Whether to move up, stay put or stop is a decision for whoever wrote the prescription.
Can you stay on a low dose of Zepbound?
Yes at 5 mg, which is the lowest dose this label recognizes as one to stay on.
The label names 5, 10 and 15 mg as doses to settle on. 5 mg is the lowest of those. Below it the label is describing a climb, not a destination.
2.5 mg is printed on the same ladder and is not on that list. The label treats it as somewhere you pass through.
The label sets doses. It does not rank them, and it does not say a higher one suits a given person better.
How does the Zepbound schedule compare with other GLP-1 brands?
Zepbound tops out at 15 mg once a week. Compare starting and ongoing doses for the 9 brands below.
The table below compares the highest labeled doses, starting doses and ongoing dose choices. Each row comes from that product’s label.
Milligrams do not carry across molecules. 15 mg of tirzepatide is not comparable to 15 mg of anything else. The last column says so on every row where the drug substance differs.
Brands can share a drug but differ in form, approved use or dose schedule. A matching milligram amount does not make products interchangeable.
| Brand | Drug | Starts at | Tops out at | Doses to stay on | Against Zepbound |
|---|---|---|---|---|---|
| Foundayo | Orforglipron | 0.8 mg daily | 17.2 mg | 5.5 mg can continue; further increases depend on response and tolerability | Different drug — milligrams do not compare |
| Zepbound | Tirzepatide | 2.5 mg weekly | 15 mg | 5, 10 and 15 mg | This page |
| Mounjaro | Tirzepatide | 2.5 mg weekly | 15 mg | 2.5 mg can continue; increases depend on blood sugar control | Same drug, same 15 mg ceiling |
| Rybelsus | Semaglutide | 3 mg daily | 14 mg | 7 and 14 mg | Different drug — milligrams do not compare |
| Wegovy | Semaglutide | 0.25 mg weekly | 7.2 mg | 1.7, 2.4 and 7.2 mg | Different drug — milligrams do not compare |
| Trulicity | Dulaglutide | 0.75 mg weekly | 4.5 mg | 0.75 mg can continue; increases depend on blood sugar control | Different drug — milligrams do not compare |
| Saxenda | Liraglutide | 0.6 mg daily | 3 mg | 2.4 and 3 mg | Different drug — milligrams do not compare |
| Ozempic | Semaglutide | 0.25 mg weekly | 2 mg | 0.5, 1 and 2 mg | Different drug — milligrams do not compare |
| Victoza | Liraglutide | 0.6 mg daily | 1.8 mg | 1.2 and 1.8 mg | Different drug — milligrams do not compare |
Do the side effects change as the dose goes up?
The main label table reports separate results for Zepbound 5 mg, Zepbound 10 mg, Zepbound 15 mg.
A trial group’s assigned dose and each dose increase are different things. The table counts reports over the study, including time spent increasing doses.
These group results cannot tell someone whether a dose change caused their symptoms. Read each result with its trial group and study period.
The Zepbound side-effect page shows the full table and the group behind each percentage. The schedule here gives the label’s timing for dose changes.
What is the most important information I should know about Zepbound?
The label’s boxed warning covers thyroid tumors in rodents
Zepbound opens with a boxed warning about thyroid C-cell tumors found in rats. It is not known whether tirzepatide does the same in people. The label rules the drug out where medullary thyroid cancer runs in the family, and where someone has the inherited condition MEN 2.
A boxed warning is the strongest warning the FDA applies. It appears at the top of the label, before the dosing section summarized here.
A lower dose does not remove the boxed warning. The warning is separate from the common side-effect percentages in trial tables.
Do not use Zepbound if:
The label lists reasons a person must not use Zepbound. The boxed warning covers some of these; the full label gives the complete list.
The label’s contraindications section lists reasons not to use the drug. The boxed warning alone is not the full list.
The label separately lists 8 serious effects it tells prescribers to watch for. Each one is set out with the label’s own wording on the Zepbound side-effect page.
The dose schedule comes from the prescribing label. Read the full label for the complete list of reasons not to take it.
What are the possible side effects of Zepbound?
The most common in the label’s own trial table is nausea, reported by 29% on Zepbound 10 mg.
That figure comes from one trial group. Its dose, study population and follow-up period matter when reading the percentage.
The trial reports effects for each assigned group over the study. Those totals do not isolate what happened after each dose increase.
The full table, every arm and the placebo column beside it, sits on the Zepbound side-effect page.
Where to read next
5 pages sit next to this one, and each answers something this page deliberately does not.
- Zepbound results at measured trial visits keeps the week-12 absence, the label endpoints and the continuation trial separate.
- Zepbound side effects, dose by dose carries the label’s own trial table.
- The tirzepatide dosage chart covers the drug rather than the brand, including the vial and syringe arithmetic no pen needs.
- Storing Zepbound safely covers the fridge, the room-temperature window and what the label leaves out.
- What Zepbound costs reads the price off the manufacturer’s own terms rather than the label, including who those terms shut out.
- Zepbound (tirzepatide) injection — FDA-approved Prescribing Information (DailyMed)retrieved 2026-09-13FDA label
- Zepbound (tirzepatide) Prescribing Information, revised 02/2026 — Drugs@FDA NDA 217806/S-042retrieved 2026-08-12FDA label
- FDA approval letter, NDA 217806 — Zepbound (tirzepatide) injection, chronic weight management in adultsretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 217806/S-013 — Zepbound for moderate to severe obstructive sleep apnearetrieved 2026-08-12FDA label